EA200000528A1 - Способ получения вакцин для предупреждения патогенных эффектов, связанных с ретровирусной инфекцией - Google Patents

Способ получения вакцин для предупреждения патогенных эффектов, связанных с ретровирусной инфекцией

Info

Publication number
EA200000528A1
EA200000528A1 EA200000528A EA200000528A EA200000528A1 EA 200000528 A1 EA200000528 A1 EA 200000528A1 EA 200000528 A EA200000528 A EA 200000528A EA 200000528 A EA200000528 A EA 200000528A EA 200000528 A1 EA200000528 A1 EA 200000528A1
Authority
EA
Eurasian Patent Office
Prior art keywords
protein
host
retrovirus
pathogenic effects
effects associated
Prior art date
Application number
EA200000528A
Other languages
English (en)
Inventor
Пьер-Франсуа Серр
Original Assignee
Иппокамп
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Иппокамп filed Critical Иппокамп
Publication of EA200000528A1 publication Critical patent/EA200000528A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Изобретение относится к способу получения вакцины против патогенных воздействий в связи с заражением хозяина ретровирусом в случае, когда клетки-мишени ретровируса имеют мембранный рецептор для белка хозяина и вирусная инфекция индуцирует иммунный ответ, направленный как против белка оболочки вируса, так и против белка хозяина. Способ состоит в приготовлении агента вакцины на основе полипептида, содержащего фрагмент иммунодоминанта и сохраненную зону белка оболочки ретровируса, в модифицированной форме, так что агент вакцины индуцирует иммунный ответ, направленный против белка оболочки, но не против белка хозяина.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200000528A 1997-11-17 1998-11-17 Способ получения вакцин для предупреждения патогенных эффектов, связанных с ретровирусной инфекцией EA200000528A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9714387A FR2771011B1 (fr) 1997-11-17 1997-11-17 Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
PCT/FR1998/002447 WO1999025377A1 (fr) 1997-11-17 1998-11-17 Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale

Publications (1)

Publication Number Publication Date
EA200000528A1 true EA200000528A1 (ru) 2001-02-26

Family

ID=9513450

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200000528A EA200000528A1 (ru) 1997-11-17 1998-11-17 Способ получения вакцин для предупреждения патогенных эффектов, связанных с ретровирусной инфекцией

Country Status (19)

Country Link
US (3) US6455265B1 (ru)
EP (1) EP1034000B1 (ru)
JP (1) JP4837823B2 (ru)
KR (1) KR20010032210A (ru)
CN (1) CN1281371A (ru)
AP (1) AP2000001841A0 (ru)
AT (1) ATE353017T1 (ru)
AU (1) AU1243499A (ru)
BR (1) BR9814204A (ru)
CA (1) CA2309676C (ru)
DE (1) DE69837012T2 (ru)
DK (1) DK1034000T3 (ru)
EA (1) EA200000528A1 (ru)
ES (1) ES2281938T3 (ru)
FR (1) FR2771011B1 (ru)
IL (2) IL136163A0 (ru)
OA (1) OA11522A (ru)
PT (1) PT1034000E (ru)
WO (1) WO1999025377A1 (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2771011B1 (fr) * 1997-11-17 2000-01-28 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
CN1396178A (zh) * 2002-06-17 2003-02-12 成都阳辉生物科技有限责任公司 抗乙肝病毒等包膜病毒感染的工程多肽及其制备方法
EP1466924B9 (en) 2003-04-11 2013-06-19 Institut Pasteur Synthetic peptide vaccines for HIV: the CBD epitope as an effective immunogen to elicit broadly neutralizing antibodies against HIV
CN1860130B (zh) 2003-07-30 2012-05-30 迈梅蒂克斯公司 新的可溶且稳定的三聚体形式的gp41多肽
EP1673633B9 (en) * 2003-09-11 2011-03-02 Idexx Laboratories, Inc. Method for detecting feline immunodeficiency virus
EP1709447B1 (en) * 2003-12-18 2009-06-24 Idexx Laboratories, Inc. Method for detecting feline immunodeficiency virus
US7348136B2 (en) * 2004-02-19 2008-03-25 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
JP5060284B2 (ja) * 2004-03-30 2012-10-31 アンスティテュ・グスターブ・ルシ ウイルスタンパク質の免疫抑制作用のモデュレーションに関与するポリペプチド配列
CA2576902C (en) * 2004-06-30 2012-05-08 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
AU2005267608B2 (en) * 2004-06-30 2009-01-15 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus (FIV) comprising the use of peptides derived from the V3 region of the FIV env protein
US20060003445A1 (en) * 2004-06-30 2006-01-05 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
US7291338B2 (en) * 2005-03-09 2007-11-06 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
US20090232826A1 (en) * 2005-05-02 2009-09-17 Mymetics Corporation Antibody or a fragment thereof, having neutralizing activity against hiv but not against il2
TWI343180B (en) * 2005-07-01 2011-06-01 Ind Tech Res Inst The acoustic wave sensing-device integrated with micro channels
WO2007099387A1 (en) * 2006-03-03 2007-09-07 Mymetics Corporation Virosome-like vesicles comprising gp41-derived antigens
CN1869704B (zh) * 2006-06-14 2010-06-30 厦门大学 快速鉴定与病原菌互作的宿主蛋白的方法
WO2010042760A2 (en) * 2008-10-08 2010-04-15 The Administrators Of The Tulane Educational Fund Compositions, methods, and kits for enhancing the immunogenicity of pathogenic antigens
KR20110126636A (ko) 2009-02-06 2011-11-23 마이메틱스 코포레이션 스플리팅 ｇｐ41
CA2750058C (en) 2009-02-06 2017-11-28 Mymetics Corporation Novel gp41 antigens
EP2467163A2 (en) * 2009-08-21 2012-06-27 Dana-Farber Cancer Institute, Inc. Mimotopes of hiv and uses thereof
US8809004B2 (en) 2010-04-02 2014-08-19 Idexx Laboratories, Inc. Detection of feline immunodeficiency virus
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
AU2013308623B2 (en) 2012-08-30 2017-03-02 Merial, Inc. Hyperbaric device and methods for producing inactivated vaccines and for refolding/solubilizing recombinant proteins
WO2021185851A1 (en) 2020-03-17 2021-09-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Vaccine compositions for hiv prevention and treatment
CN111701016A (zh) * 2020-06-28 2020-09-25 张全志 逆转录病毒原病毒序列在逆转录病毒疫苗设计中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993001304A1 (en) * 1991-07-10 1993-01-21 Synbiotics Corporation Synthetic peptides related to fiv-env proteins
NZ254640A (en) * 1992-07-20 1997-04-24 Univ Duke Hiv protein fragments of transmembrane glycoprotein gp41 (dp-107) with antiviral activity and their use
GB9219936D0 (en) * 1992-09-21 1992-11-04 Pitman Moore Inc Vaccines
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US6017536A (en) * 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
FR2771011B1 (fr) * 1997-11-17 2000-01-28 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale

Also Published As

Publication number Publication date
BR9814204A (pt) 2000-10-03
EP1034000B1 (fr) 2007-01-31
PT1034000E (pt) 2007-05-31
IL136163A (en) 2007-07-04
ES2281938T3 (es) 2007-10-01
WO1999025377A1 (fr) 1999-05-27
AP2000001841A0 (en) 2000-06-30
EP1034000A1 (fr) 2000-09-13
KR20010032210A (ko) 2001-04-16
US6455265B1 (en) 2002-09-24
US20080003229A1 (en) 2008-01-03
JP2001524456A (ja) 2001-12-04
US20040014046A1 (en) 2004-01-22
ATE353017T1 (de) 2007-02-15
FR2771011B1 (fr) 2000-01-28
DE69837012T2 (de) 2007-11-29
DK1034000T3 (da) 2007-06-04
DE69837012D1 (de) 2007-03-22
OA11522A (fr) 2004-02-09
CN1281371A (zh) 2001-01-24
AU1243499A (en) 1999-06-07
IL136163A0 (en) 2001-05-20
US7253270B2 (en) 2007-08-07
FR2771011A1 (fr) 1999-05-21
CA2309676A1 (fr) 1999-05-27
US7829683B2 (en) 2010-11-09
CA2309676C (fr) 2012-08-07
JP4837823B2 (ja) 2011-12-14
US20050048478A9 (en) 2005-03-03

Similar Documents

Publication Publication Date Title
EA200000528A1 (ru) Способ получения вакцин для предупреждения патогенных эффектов, связанных с ретровирусной инфекцией
ATE325882T1 (de) Polypeptide, die mit alfalfamosaikviralen oder ilarviralen kapsiden fusioniert sind
ES2002490A6 (es) Un metodo de preparar un virus recombinante
CA2297786A1 (en) New immunoprotective influenza antigen and its use in vaccination
EP1001032A3 (en) Recombinant retroviruses delivering vector constructs to target cells
NZ219113A (en) Hiv peptide containing epitope of the env protein
DE3588022D1 (de) Pre-S-Gen kodierte Hepatitis-B immunogene Peptide, Vakzine, Diagnostika und synthetische lipidische Bläschenträger.
ATE258188T1 (de) Retro-, inverso-, und retro-inverso synthetische peptidanaloge
ATE144143T1 (de) Künstlicher impfstoff gegen aids-virus
DK33190D0 (da) Hiv-3 retrovirus og anvendelse heraf
DK0480949T3 (da) Fremstilling af virus og oprensning af virale kappeproteiner til vaccineanvendelse
FI885296A0 (fi) Rekombinant hiv-2 polypeptid.
EP0236977A3 (en) Bovine virus diarrhea and hog cholera vaccines
PT625157E (pt) Epitopes p1a1 e p1a2 da gpiiia da plaqueta sua preparacao e utilizacao
Dueñas‐Carrera et al. Enhancement of the immune response generated against hepatitis C virus envelope proteins after DNA vaccination with polyprotein‐encoding plasmids
NO175846C (no) Fremgangsmåte for å oppnå et immunogen
ATE208421T1 (de) Stimulierung der immunantwort durch virales protein
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained
Platzer et al. Identification of an immunodominant region on the isolated bovine leukaemia virus (BLV) major envelope protein gp51 by monoclonal antibodies presumably not exposed during natural BLV infection.
Orlik et al. Polyclonal bovine sera but not virus-neutralizing monoclonal antibodies block bovine leukemia virus (BLV) gp51 binding to recombinant BLV receptor BLVRcp1
EP0320034A3 (en) New immunologically active synthetic peptides useful for preparing an antimalarial vaccine
Bouges-Bocquet et al. In vitro genetic constructions devised to express given antigenic determinants at the surface of gram-negative bacteria.
DK284389D0 (da) Precursorantigener
GB8913665D0 (en) Method of preparing vaccines against rna viruses